Norovirus cases are significantly increasing in the US and Canada. Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical trials, with the potential to be the first approved ...

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

leading to severe symptoms and, in some cases, hospitalization,” said Stéphane Bancel, CEO of Moderna, in a statement last fall. “By advancing our investigational norovirus vaccine into a ...

There are currently three vaccine candidates moving through the clinical pipeline in human trials right now, and the furthest along is Moderna, which has developed a norovirus vaccine with the ...

Be it from tap water on a vacation, some dodgy chicken, or something the kids have brought home from school, we've almost all ...

Moderna is developing an mRNA-based vaccine, currently in Phase 3 clinical ... Fever or headaches may also occur. Symptoms usually develop 12 to 48 hours after being exposed, and recovery ...

Since 2023, Moderna has been studying a vaccine to keep people from getting infected with H5N1, which has been decimating flocks of birds throughout the nation. It has also run rampant in herds of ...

Moderna is recruiting adult participants for Nova 301, its Phase 3 clinical trial evaluating an investigational norovirus vaccine called mRNA-1403.

Moderna intends to use the above-mentioned funds to support the late-stage development of mRNA-1018, its investigational pandemic influenza vaccine against H5 and H7 avian influenza viruses.

Massachusetts-based Moderna will likely be the first to manufacture a bird flu vaccine, backed by hundreds of millions in government funding. The biopharmaceutical giant is developing the vaccine ...